经皮冷冻消融治疗肌肉骨骼肿瘤:最大单中心病例系列报告的结局、并发症与亚组分析
结果显示58%患者获良好或完全缓解,15%部分缓解,94%患者CT值下降,总并发症率6.3%,无严重并发症或手术相关死亡。作者认为冷冻消融对选择性肌肉骨骼肿瘤安全有效,但CT值下降作为影像学反应标志尚待验证。
要点
- 经皮冷冻消融治疗选择性肌肉骨骼肿瘤安全有效,总并发症率仅6.3%,无严重并发症。
- 94%患者术后CT值下降,可作为影像学反应的探索性补充指标,但尚未验证。
- 58%患者获良好或完全缓解,15%部分缓解,需结合临床与影像综合评估疗效。
核心结论
- 经皮冷冻消融对选择性肌肉骨骼肿瘤是安全有效的微创治疗,多数患者获良好、完全或部分缓解,并发症率低。
- 术后CT值下降可能是有用的影像学反应标志,但尚未经验证,需进一步前瞻性研究确认。
研究设计与样本
- 单中心回顾性队列研究,在三级肌肉骨骼肿瘤中心开展,所有操作由单一具有20余年经验的专科肌肉骨骼介入放射科医生完成。
- 中位随访3个月(均值8.7个月,范围0-48个月),评估临床反应、影像学反应、复发和并发症;影像学反应采用治疗前后CT的Hounsfield单位(HU)测量,作为探索性补充标志。
- 并发症采用CIRSE分类系统分级。
诊断标准与关键数值
- 良好或完全缓解见于28例(58%),部分缓解见于7例(15%)。
- 48例中45例(94%)观察到HU下降。
- 总并发症率为6.3%(48例手术中记录3例并发症),无严重并发症或手术相关死亡。
临床应用与阅片要点
- 对选择性肌肉骨骼肿瘤患者,经皮冷冻消融可作为微创治疗选项,阅片时注意评估术后CT值变化作为影像学反应的探索性参考。
- 报告并发症时可采用CIRSE分类系统分级,本组无严重并发症,提示该技术安全性较好。
- CT值下降虽常见但非验证标准,需结合临床反应综合判断,避免仅凭HU变化判定疗效。
局限性
- 单中心回顾性设计,所有操作由单一术者完成,结果外推性受限。
- 中位随访仅3个月,随访时间较短,部分患者随访范围宽(0-48个月),长期复发率数据有限。
- 影像学反应采用HU测量,非验证的放射学评分系统,仅为探索性补充标志。
- 样本量48例,亚组分析效力有限;作者指出需前瞻性研究、更长随访、标准化反应标准和验证的并发症分级来确认发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Cryoablation is an image-guided, minimally invasive treatment technique that uses extreme cold to induce tumour destruction. Its role in musculoskeletal oncology has expanded in recent years, although large clinical series remain limited. This study reports a large single-centre experience of percutaneous cryoablation for musculoskeletal tumours, including metastatic lesions, benign and cartilaginous tumours, and primary bone tumours.
MATERIALS AND METHODS: This was a single-centre retrospective cohort study conducted at a tertiary musculoskeletal oncology centre. All procedures were performed by a single specialist musculoskeletal interventional radiologist with over 20 years of experience. The study included patients who underwent percutaneous cryoablation for musculoskeletal tumours between June 2021 and December 2025. Clinical response, radiological response, recurrence, and complications were assessed over a median follow-up of 3 months (mean 8.7 months; range 0-48 months). Radiological response was assessed using pre-treatment and post-treatment Hounsfield Unit (HU) measurements on CT; this is not a validated radiological scoring system and is reported as a complementary, exploratory marker alongside standard clinical response assessment. Complications were graded using the CIRSE classification system.
RESULTS: A total of 48 patients underwent percutaneous cryoablation during the study period. The cohort included 26 males and 22 females, with a median age of 40 years. A good or complete response was achieved in 28 patients, representing 58% of the total cohort. A partial response was achieved in seven patients, representing 15% of the total cohort. HU reduction was observed in 45 of 48 patients, representing 94% of the cohort. The overall complication rate was 6.3%, with three complications recorded among 48 procedures. No major complications or procedure-related deaths were observed.
CONCLUSIONS: Cryoablation appears to be a safe and effective minimally invasive treatment for selected musculoskeletal tumours. Most patients achieved a good, complete, or partial response, with a low complication rate. Hounsfield Unit reduction after treatment may provide a useful, though as yet non-validated, marker of radiological response. Further prospective studies with longer follow-up, standardised response criteria and validated complication grading are needed to confirm these findings.
引用
- Thompson B, Gibson J, Kiyawat V, et al. Percutaneous cryoablation of musculoskeletal tumours: the largest reported single-centre case series - outcomes, complications and subgroup analysis. Skeletal Radiol. 2026. PMID: 42909541. doi:10.1007/s00256-026-05404-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。